Worth Venture Partners’s Allena Pharmaceuticals ALNA Stock Holding History

Worth Venture Partners’s Portfolio ALNA Stock Details ALNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-980,200	Closed	-$581K	–	166
2021 Q4	$581K	Hold	980,200	–	–	0.29%	78
2021 Q3	$884K	Buy	980,200 +236,000	+32%	+$231K	0.4%	67
2021 Q2	$967K	Sell	744,200 -236,000	-24%	-$286K	0.36%	69
2021 Q1	$1.36M	Buy	980,200 +470,000	+92%	+$783K	0.66%	44
2020 Q4	$653K	Buy	510,200 +101,360	+25%	+$141K	0.52%	54
2020 Q3	$605K	Buy	408,840 +153,840	+60%	+$216K	0.5%	50
2020 Q2	$403K	Buy	255,000 +152,206	+148%	+$256K	0.2%	70
2020 Q1	$99K	Sell	102,794 -141,392	-58%	-$283K	0.06%	89
2019 Q4	$667K	Buy	+244,186	New	+$802K	0.33%	37

Other funds holding ALNA

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Worth Venture Partners's ALNA Position: Q1 2022 in Review

Worth Venture Partners sold out of Allena Pharmaceuticals (ALNA) in Q1 2022, closing a stake of 980,200 shares — an estimated $581K sold.

Worth Venture Partners first reported a position in ALNA in Q4 2019 and held it in 9 quarters. The position peaked at $1.36M in Q1 2021. 28 funds tracked by Wall St. Rank hold ALNA as of Q1 2022.

Worth Venture Partners reported no remaining Allena Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Worth Venture Partners sold 980,200 Allena Pharmaceuticals shares in Q1 2022, an estimated $581K.
Worth Venture Partners first reported a position in Allena Pharmaceuticals in Q4 2019 and held it in 9 quarters.
Worth Venture Partners's Allena Pharmaceuticals position peaked at $1.36M in Q1 2021.
28 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q1 2022.

Based on Worth Venture Partners's 13F filing for Q1 2022, filed 16 May 2022.